Milestone Scientific Announces Publication of Clinical Study in Hair Transplantation.

Business/Technology Editors & Medical/Health Writers

LIVINGSTON, N.J.--(BUSINESS WIRE)--June 18, 2002

Milestone Scientific Inc. (AMEX: MS) today announced the publication of a favorable clinical study using the company's CompuMed(TM)computer-controlled local anesthetic delivery system.

The study, conducted by Robert H. True, MD, MPH, FABFP, ABHRS and Robert Elliott, MD, ABHRS from Elliott and True Medical Group PC, which will be published in the June issue of Dermatologic Surgery, evaluated the pain and pain perception of three distinct groups of patients. The first group consisted of over 100 patients who had a previous hair transplantation session performed by standard injection technique. In this group, 51% reported moderate to severe pain during standard injection. This dropped to 5% with CompuMed(TM).

The second group consisted of patients who had undergone hair transplantation treatment by doctors outside of the Elliott and True Medical Group. Statistically significant pain reduction was demonstrated not only during treatment but during the first 48 hours postoperatively. The final group consisted of prospective evaluation of 88 patients using CompuMed(TM) versus standard injection. Again, the CompuMed(TM) superiority was statistically significant. In looking at all three studies combined, 68% of all patients described experiencing no discomfort or very slight discomfort.

The authors have used CompuMed(TM), featuring The Wand(R) handpiece in over 5,000 cases. They found that even using optimal hypodermic syringe injection techniques, the superiority of CompuMed(TM) was evident. Importantly, they also noted a significant reduction of pain during the postoperative period. Finally, the authors noticed that the amount of anesthetic required was decreased.

"The study published by Drs. Elliott and True, scientifically validates the use of computer-controlled local anesthetic delivery in hair transplantation, comments Stuart Wildhorn, Senior Vice President for Milestone Scientific. Consumers now have a choice when they go the doctor, whether it is for hair transplantation, both minor and major podiatric surgeries, dermatological procedures, nasal and sinus surgery as well as dentistry. The system has also proven effective at reducing the need for IV sedation, which of course minimizes risk and decreases cost. Milestone's CompuFlo(TM) technology has been proven to be effective in the delivery of conscious sedation during sinus and nasal surgery. This important development is quite significant, as it will reduce the need for general anesthesia, thereby minimizing the attendant risks."

Furthermore, in an article published in the June issue of Podiatry Today, three current users were interviewed. Adam Landsman, DPM, PhD, calls the CompuMed(TM) system "fascinating" and "can't say enough about it." Dr. Landsman, the Director of Research at the Scholl College of Podiatric Medicine at Finch University, has used the system on over 160 patients and claims the biggest benefit is the "no pain" factor. He also considers the system to be cost-effective and has more than paid for itself, as he has had 30-40 referrals due to its use in his practice.

Milestone Scientific is the developer, manufacturer and marketer of CompuMed(TM) and CompuDent(TM) computer controlled local anesthetic delivery systems. These systems comprise a microprocessor controlled drive unit as well as The Wand(R) handpiece, a single patient use product that is held in a pen like manner for injections. In 2001, Milestone Scientific received broad United States patent protection on "CompuFlo(TM)", an enabling technology for computer controlled, pressure sensitive infusion, perfusion, suffusion and aspiration, which provides real time displays of pressures, fluid densities and flow rates, that advances the delivery and removal of a wide array of fluids. Milestone Scientific recently received United States patent protection on a safety engineered sharps technology, which allows for fully automated true single-handed activation with needle anti-deflection and force-reduction capability.

This release contains "forward looking statements" based on current expectations but involving known and unknown risks and uncertainties. Actual results or achievements may be materially different from those expressed or implied. The Company's plans and objectives are based on assumptions involving judgments with respect to future economic, competitive and market conditions, and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Therefore, there can be no assurance that the forward-looking statements, including, but not limited to, those relating to the availability of capital pursuant to this facility, will prove to be accurate.